The price reached 1.52 post IPO.
Diagnostic referrals were +34% last quarter and this revenue segment will only accelerate as confidence returns. There is going to be a major backlog of diagnostics demand coming out of Covid.
All major listed Telehealth peer valuations have been pricked. DOC has similarly cratered -50% off its all time high and trading at a very low 4x EV/Revenue basis for 2021. Lowest of all peers.
For this level of growth its a massive discount.
Ann: Interim Financial Report, Appendix 4D & Outlook, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
